Expertise in
11
conditions

Dr. Nicholas J. Farrell

Maryland Oncology Hematology PA
Laurel, MD
Expertise in
11
conditions
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
OverviewInsuranceLocationsClinical Research

Overview

Nicholas Farrell is a Hematologist Oncology specialist and an Oncologist in Laurel, Maryland. Dr. Farrell is highly rated in 11 conditions, according to our data. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Endometrial Cancer, and Childhood Iron Deficiency Anemia. Dr. Farrell is currently accepting new patients.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in MD
Hospital Affiliations
Suburban Hospital
Adventist Healthcare Shady Grove Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  UnitedHealthcare

Locations

MARYLAND ONCOLOGY HEMATOLOGY PA
7350 Van Dusen Rd, Suite 370, Laurel, MD 20707
301-982-9800
Other Locations
MARYLAND ONCOLOGY HEMATOLOGY PA
6420 Rockledge Dr, Suite 4200, Bethesda, MD 20817
301-929-0765
MARYLAND ONCOLOGY HEMATOLOGY PA
11886 Healing Way, Silver Spring, MD 20904
301-933-3216

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib
An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib
Enrollment Status: Active_not_recruiting
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 4
A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: February 09, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

4 Total Publications

Transdermal microneedles for the programmable burst release of multiple vaccine payloads.
Transdermal microneedles for the programmable burst release of multiple vaccine payloads.
Journal: Nature biomedical engineering
Published: April 15, 2019
Similar Doctors
Expertise in
19
conditions
Dr. Bruce D. Cheson
Hematology | Hematology Oncology | Oncology
Expertise in
19
conditions
Dr. Bruce D. Cheson
Hematology | Hematology Oncology | Oncology

American Oncology Partners PA

106 Irving St Nw, Suite 4100, 
Washington, DC 
 (13.1 mi)
202-726-0941
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bruce Cheson is a Hematologist and a Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Cheson is highly rated in 19 conditions, according to our data. His top areas of expertise are Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Cheson is currently accepting new patients.

Expertise in
34
conditions
Dr. Craig M. Kessler
Hematology Oncology | Hematology | Oncology
Expertise in
34
conditions
Dr. Craig M. Kessler
Hematology Oncology | Hematology | Oncology

Mgmc LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (16.1 mi)
202-444-3700
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Kessler is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Kessler is highly rated in 34 conditions, according to our data. His top areas of expertise are Blood Clots, Hemophilia A, Acquired Hemophilia, Bone Marrow Aspiration, and Splenectomy. Dr. Kessler is currently accepting new patients.

Expertise in
12
conditions
Dr. Giuseppe Giaccone
Hematology Oncology | Oncology | Hematology
Expertise in
12
conditions
Dr. Giuseppe Giaccone
Hematology Oncology | Oncology | Hematology
10 Center Dr, 
Bethesda, MD 
 (13.4 mi)
301-402-3415
Languages Spoken:
English

Giuseppe Giaccone is a Hematologist Oncology specialist and an Oncologist in Bethesda, Maryland. Dr. Giaccone is highly rated in 12 conditions, according to our data. His top areas of expertise are Thymic Epithelial Tumor, Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile